Biotech: Page 2


  • Ampoules of Novavax's COVID-19 vaccine prepared in Berlin, Germany.
    Image attribution tooltip
    Carsten Koall/Getty Images via Getty Images
    Image attribution tooltip

    What’s next for COVID dark horse Novavax?

    Novavax scored a new COVID vaccine go-ahead for the 2023-24 season, but is it the boost the company needs?

    By Kelly Bilodeau • Oct. 30, 2023
  • Helen Sabzevari header
    Image attribution tooltip
    Permission granted by Precigen
    Image attribution tooltip
    Q&A // Red Jacket winners 2023

    Red Jacket: Helen Sabzevari, an immunotherapy pioneer

    Precigen’s CEO is pushing for her next therapeutic breakthrough with innovative cell and gene therapy platforms.

    By Oct. 27, 2023
  • women's health Explore the Trendline
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Trendline

    Women's health

    As women’s health investments explode, major opportunities for growth remain.

    By PharmaVoice staff
  • Jeremy Levin, CEO and chairman, Ovid Therapeutics
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip
    Q&A // Red Jacket winners 2023

    Red Jacket: Dr. Jeremy Levin, a transformational leader

    A consummate life sciences executive who has led with boldness and devotion, Dr. Jeremy Levin considers himself a participant as well as a leader.

    By Oct. 27, 2023
  • 2023 Red Jacket header
    Image attribution tooltip

    Photo illustration: Industry Dive

    Image attribution tooltip

    The 2023 Red Jacket honorees

    This year's inductees to the PharmaVoice 100 "hall of fame" are leaders who have been at the forefront — and will stay at the forefront — of industry change.

    By Oct. 27, 2023
  • vaccine ampoules on red
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    Cidara’s J&J-partnered immunotherapy could target flu and cancer

    On a roll with promising data, the commercial-stage biotech is leveraging drug-Fc conjugates to aim a new weapon at viral targets.

    By Alexandra Pecci • Oct. 26, 2023
  • Patient group
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Patient groups have become a powerhouse in R&D. Here’s a look at their impact.

    “They have the money,” and they’re using it to influence drug development, according to the executive director of the IQVIA Institute for Human Data Science.

    By Kelly Bilodeau • Oct. 25, 2023
  • Meningococcal vaccine
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Pfizer’s new shot approval adds to a growing vaccine prowess

    Pfizer brought in a new approval for a five-in-one shot for meningococcal disease, and the company has built a sizable vaccine business over time.

    By Oct. 24, 2023
  • Antibodies autoimmune disease
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    An ‘inverse vaccine’ takes aim at autoimmune diseases

    Backed by Pfizer, Anokion’s innovative approach to treating celiac, MS and more is showing early promise where others failed.

    By Kelly Bilodeau • Oct. 23, 2023
  • rainforest pill
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    From the rainforest to Wall Street — Jaguar Health’s big play for revitalization

    A pharma with a massive collection of rainforest-derived plants needs a regulatory win to overcome last year’s financial decline.

    By Kelly Bilodeau • Oct. 17, 2023
  • Physicians, researchers and healthcare professionals attend ASCO's annual Meeting on June 2, 2023 in Chicago.
    Image attribution tooltip

    ASCO / Nick Agro

    Image attribution tooltip

    The top biopharma conferences in 2024

    A few key meetings remain this year, like ESMO and ASH, while next year’s events are already being planned. Here’s a list of conferences to keep in mind.

    By Ned Pagliarulo • Oct. 16, 2023
  • PV100 category rare disease warriors
    Image attribution tooltip

    Photo illustration: Industry Dive; Getty Images

    Image attribution tooltip
    PharmaVoice 100

    PharmaVoice 100s: Rare disease warriors

    Biopharma leaders pounding away at rare diseases so patients with few other options can have healthier lives.

    By Oct. 16, 2023
  • Aging clock melting
    Image attribution tooltip
    Getty Images via Getty Images
    Image attribution tooltip

    Has the science of anti-aging caught up with the dream of a longer life?

    Billionaire investors and a new crop of longevity biotechs are betting big money on a lifespan-altering tipping point.

    By Kelly Bilodeau • Oct. 16, 2023
  • corporate brand
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Opinion

    Branded: The trademarks pharma leaders look up to

    What do brands like Patagonia, Nike and Lego have to do with pharma? Here are some of the brands industry leaders relate to most — and how they inspire work in the life sciences.

    By PharmaVoice Staff • Oct. 13, 2023
  • A close up a cell with a large screen in the background displaying a injection needle.
    Image attribution tooltip

    Gregor Fischer/DPA/Newscom

    Image attribution tooltip
    Deep Dive

    A decade later, biotech’s CRISPR revolution is still going strong

    Once the specialty of a few select drugmakers, CRISPR gene editing is now an essential technology for a growing group of biotechs, many led by former students of the field's pioneering scientists.

    By Gwendolyn Wu , , Oct. 12, 2023
  • Alnylam Pharmaceuticals CEO Yvonne Greenstreet
    Image attribution tooltip
    Permission granted by Alnylam/Yvonne Greenstreet
    Image attribution tooltip

    Alnylam CEO, ‘disappointed’ with FDA’s Onpattro rejection, pivots to the future

    Yvonne Greenstreet, CEO of RNAi specialist Alnylam, addressed the surprise move by regulators and the company’s new future plans.

    By Oct. 12, 2023
  • Image attribution tooltip

    Permission granted by Mike Rea.

    Image attribution tooltip
    Q&A

    5 minutes with — IDEA Pharma’s Mike Rea

    The CEO on the secrets of innovative pharma companies, his record collection and what he’d always rather be doing.

    By Oct. 11, 2023
  • pediatric cancer concept
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Q&A // Biotech Spotlight

    To close the pediatric innovation gap, this biotech has to think differently

    Day One Biopharmaceuticals is bucking the cancer drug development trend by working with children and adults simultaneously.

    By Alexandra Pecci • Oct. 11, 2023
  • The logo of Google Cloud is seen at the 2023 Hannover Messe industrial trade fair on April 17, 2023 in Hanover, Germany.
    Image attribution tooltip
    Alexander Koerner / Stringer via Getty Images
    Image attribution tooltip

    Google bets on AI in the life sciences as ‘technology for a purpose’

    A life sciences exec at Google Cloud talks about the future and fears for using AI in pharma.

    By Alexandra Pecci • Oct. 10, 2023
  • bone study in space
    Image attribution tooltip
    Permission granted by Dr. Chia Soo
    Image attribution tooltip

    Research in space yields clues about boosting bone health on Earth

    A study aimed at helping astronauts decrease bone loss could open the door to novel osteoporosis meds.

    By Kelly Bilodeau • Oct. 10, 2023
  • dna tube
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip
    Biotech Spotlight

    A biotech ‘tuning’ the genome for a potentially safer gene therapy

    Tune Therapeutics is hoping to overcome the pitfalls of CRISPR-style treatments with epigenetic editing.

    By Kelly Bilodeau • Oct. 9, 2023
  • conference crowd
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Key upcoming events for pharma execs

    Trade shows and events focused on the industry’s hot-button topics, technologies and trends.

    By Oct. 6, 2023
  • Emil Kakkis
    Image attribution tooltip

    Permission granted by Dr. Emil Kakkis.

    Image attribution tooltip

    FDA’s ‘ivory tower thinking’ ignores promising biomarkers, says a rare disease CEO

    The FDA wouldn’t review a drug that was 90% effective. In rare diseases, this is too common, said Ultragenyx CEO Dr. Emil Kakkis and a leading rare disease researcher.

    By Oct. 5, 2023
  • a unicorn chess piece sits on top of a stack of coins
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    Where have all the unicorns gone? A look at 4 billion-dollar biotechs

    Not every unicorn company lives up to its $1 billion promise. Here are four worth watching.

    By Alexandra Pecci • Oct. 3, 2023
  • A photograph of the exterior of the Food and Drug Administration headquarters in Maryland.
    Image attribution tooltip
    Sarah Silbiger via Getty Images
    Image attribution tooltip

    5 FDA decisions to watch in the fourth quarter

    The regulator is considering approval of what would be the first CRISPR medicine, as well as important clearances for Alnylam, Bristol Myers, Amgen and Pfizer.

    By Ned Pagliarulo , Jonathan Gardner • Oct. 2, 2023
  • Puzzle of the human heart and doctor hand with the missing piece of puzzle
    Image attribution tooltip
    Stock via Getty Images
    Image attribution tooltip

    The ALS therapy keeping the human pig heart transplant pumping

    Eledon’s investigational ALS drug tegoprubart could also help prevent organ transplant rejections, the company says.

    By Kelly Bilodeau • Oct. 2, 2023